Download PDF
Psychiatr Prax 2003; 30: 216-220
DOI: 10.1055/s-2003-39747
Biologische Psychiatrie
© Georg Thieme Verlag Stuttgart · New York

Liquorfiltration als experimentelle Therapie bei therapieresistenten Psychosen Borna-Disease-Virus-seropositiver Patienten

Therapeutische Effekte, BefundeCSF Filtration as Experimental Therapy in Therapyresistant Psychoses in Borna Disease Virus-Seropositive PatientsTherapeutic Effects, FindingsKarl  Bechter1 , Volkhard  Schreiner1 , Sibylle  Herzog3 , Norbert  Breitinger2 , Kurt  H.  Wollinsky5 , Heinrich  Brinkmeier4 , Peter  Aulkemeyer4 , Frank  Weber4 , Reinhold  Schüttler1
  • 1Abteilung Psychiatrie II der Universität Ulm, Bezirkskrankenhaus Günzburg
  • 2Abteilung Neurologie und Neurologische Rehabilitation, Bezirkskrankenhaus Günzburg
  • 3Institut für Virologie, Justus-Liebig-Universität Gießen
  • 4Abteilung Allgemeine Physiologie der Universität Ulm
  • 5Abteilung Anästhesiologie und Intensivmedizin, RKU Ulm
Diese Forschungen wurden unterstützt durch die Theodore and Vada Stanley-Foundation, Bethesda/USA
Further Information

Publication History

Publication Date:
04 June 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Eine milde Borna-Disease-Virus-Enzephalitis mag einer Subgruppe affektiver oder schizophrener Spektrumpsychosen zugrunde liegen. Deshalb haben wir vier BDV-seropositive Patienten mit therapieresistenten schizophrenen oder affektiven Psychosen in einer experimentellen Add-on-Therapie mit Liquorfiltration (CSFF) behandelt. CSFF stellt eine effektive immunmodulatorische Therapie bei Guillain-Barré-Syndrom, einer autoimmuninflammatorischen neurologischen Erkrankung, dar. CSFF erscheint nach diesen ersten Ergebnissen auch bei therapieresistenten Psychosen effektiv zu sein.

Abstract

According to previous investigations, mild Borna disease virus encephalitis may underlie a subgroup of affective or schizophrenic type psychoses. And virus-induced immune pathology may underlie even a larger subgroup of psychoses. We treated BDV seropositive patients suffering from therapy resistant schizophrenic or affective spectrum psychoses by cerebrospinal fluid filtration (CSFF) in an experimental add-on treatment. CSFF was shown previously to be an effective immune modulatory treatment in autoimmune neurological disease, Guillain-Barré syndrome. CSFF appears to be an effective treatment in therapy resistant psychosis also, but only 4 patients were treated yet.

Literatur

  • 1 Bechter K. Borna Disease Virus. Mögliche Ursache neurologischer und psychiatrischer Störungen des Menschen. In: Hippius H, Janzarik W, Müller C Monographien aus dem Gesamtgebiete Psychiatrie. Darmstadt; Steinkopff 1998
    Google Scholar
  • 2 Herzog S, Rott R. Replication of Borna disease virus in cell cultures.  Med Microbiol Immunol. 1980;  168 153-158
    PubMedGoogle Scholar
  • 3 Richt J A, Alexander R C, Herzog S, Hooper D C, Kean R, Spitsin S, Bechter K, Schüttler R, Feldmann H, Heiske A, Fu Z F, Dietzschold B, Rott R, Koprowski H. Failure to detect Borna disease virus infection in peripheral blood leukocytes from humans with psychiatric disorders.  J Neurovirol. 1997;  3 174-178
    PubMedGoogle Scholar
  • 4 Herzog S, Pfeuffer I, Haberzettl K, Feldmann H, Frese K, Bechter K, Richt J A. Molecular characterization of Borna disease virus from naturally infected animals and possible links to human disorders.  Arch Virol. 1997;  131 (Suppl) 183-190
    PubMedGoogle Scholar
  • 5 Nübling C M, Kurth R. and Borna Virus Study Group .Abstracts of the Borna Virus Meeting. Freiburg/Germany; 27. - 29. Sept. 1998
    Google Scholar
  • 6 Ludwig H, Bode L. Borna disease virus: new aspects on infection, disease, diagnosis and epidemiology.  Rev Sci Tech. 2000;  19 259-288
    PubMedGoogle Scholar
  • 7 Richt J A, Rott R. Borna disease virus: a mystery as an emerging zoonotic pathogen.  Vet J. 2001;  161 24-40
    CrossrefPubMedGoogle Scholar
  • 8 Carbone K M. Borna disease virus and human disease.  Clin Microbiol Rev. 2001;  14 513-527
    CrossrefPubMedGoogle Scholar
  • 9 Lieb K, Staeheli P. Borna disease virus - does it infect humans and cause psychiatric disorders?.  Rev Clin Virol. 2001;  21 119-127
    PubMedGoogle Scholar
  • 10 Schwemmle M. Borna disease virus infection in psychiatric patients: are we on the right track?.  Lancet Infect Dis. 2001;  1 46-52
    PubMedGoogle Scholar
  • 11 Bechter K. Mild encephalitis underlying psychiatric disorder - A reconsideration and hypothesis exemplified on Borna disease.  Neurol Psychiatry Brain Res. 2001;  9 1-16
    PubMedGoogle Scholar
  • 12 Herzog S, Frese K, Richt J A, Rott R. Ein Beitrag zur Epizootiologie der Bornaschen Krankheit beim Pferd.  Wien Tierärztl Mschr. 1994;  81 374-379
    PubMedGoogle Scholar
  • 13 Reiber H. Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases.  Mult Scler. 1998;  4 99-107
    CrossrefPubMedGoogle Scholar
  • 14 Bechter K, Herzog S, Behr W, Schüttler R. Investigations of cerebrospinal fluid in Borna disease virus seropositive psychiatric patients.  Eur Psychiatry. 1995;  10 250-258
    CrossrefPubMedGoogle Scholar
  • 15 Wollinsky K H, Hülser P J, Brinkmeier H, Mehrkens H H, Kornhuber H H, Rüdel R. Filtration of cerebrospinal fluid in acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome).  Ann Med Interne. 1994;  145 451-458
    PubMedGoogle Scholar
  • 16 Wollinsky K H, Hülser P J, Brinkmeier H, Aulkemeyer P, Bössenecker W, Huber-Hartmann K H, Rohrbach P, Schreiber H, Weber F, Kron M, Büchele G, Mehrkens H H, Ludolph A C, Rüdel R. CSF filtration is an effective treatment of Guillain-Barré syndrome: A randomized clinical trial.  Neurology. 2001;  57 774-780
    PubMedGoogle Scholar
  • 17 Rott R, Becht H. Natural and Experimental Borna Disease in Animals. In: Koprowski H, Lipkin WI (eds) Borna Disease. Curr Top Microbiol Immunol. Berlin; Springer 1995: 17-30
    Google Scholar
  • 18 Bilzer T, Stitz L. Immunopathogenesis of virus disease affecting the central nervous system.  Crit Rev Immunol. 1996;  16 145-222
    PubMedGoogle Scholar
  • 19 Bechter K, Herzog S, Schreiner V, Wollinsky K H, Schüttler R. Cerebrospinal fluid filtration in a case of schizophrenia related to „subclinical” Borna disease virus encephalitis. In: Müller N Psychiatry, Psychoneuroimmunology, and Viruses. Key Top Brain Res. Wien; Springer 1999: 19-35
    Google Scholar
  • 20 Peuskens J. The evolving definition of treatment resistance.  J Clin Psychiatry. 1999;  60 (Suppl 12) 4-8
    PubMedGoogle Scholar
  • 21 Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria.  Eur Neuropsychopharmacol. 1999;  9 83-91
    CrossrefPubMedGoogle Scholar
  • 22 Weber F, Brinkmeier H, Aulkemeyer P, Wollinsky K H, Rüdel R. A small sodium channel blocking factor in the cerebrospinal fluid is preferentially found in Guillain-Barré syndrome: a combined cell physiological and HPLC study.  J Neurol. 1999;  246 955-960
    PubMedGoogle Scholar
  • 23 Aulkemeyer P, Hausner G, Brinkmeier H, Weber F, Würz A, Heidenreich F, Rüdel R. The small sodium-channel blocking factor in the cerebrospinal fluid of multiple sclerosis patients is probably an oligopeptide.  J Neurol Sci. 2000;  172 49-54
    CrossrefPubMedGoogle Scholar
  • 24 Brinkmeier H, Aulkemeyer P, Wollinsky K H, Rüdel R. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system.  Nature Med. 2000;  6 808-811
    PubMedGoogle Scholar
  • 25 Oleszak E L, Kuzmak J, Hogue B, Parr R, Collisson E W, Rodkey L S, Leibowitz J L. Molecular mimicry between Fc receptor and S peplomer protein of mouse hepatitis virus, bovine corona virus, and transmissible gastroenteritis virus.  Hybridoma. 1995;  14 1-8
    PubMedGoogle Scholar
  • 26 Oleszak E, Lin W L, Chang J R, Herzog S, Bechter K. Clonally expanded T cells are present in the CSF of patients with major depression.  World J Biol Psychiatry. 2001;  2 60
    PubMedGoogle Scholar
  • 27 Rother S, Knoblauch K D, Kirschfink M. Filtration of liquor cerebrospinalis (CSF-filtration): technical concept and filter performance under in vitro conditions.  Neuropsychiatrie. 1995;  9 82-85
    PubMedGoogle Scholar
  • 28 Waxman S G. Do „demyelinating” diseases involve more than myelin?.  Nature Med. 2000;  6 738-739
    PubMedGoogle Scholar
  • 29 Meeker R B, Robertson K, Barry T, Hall C. Neurotoxicity of CSF from HIV-infected humans.  J Neurovirol. 1999;  5 507-518
    PubMedGoogle Scholar
  • 30 Xiong H, Zeng Y C, Zheng J, Thylin M, Gendelman H E. Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia.  J Neurovirol. 1999;  5 519-528
    PubMedGoogle Scholar
  • 31 Kienle G S, Kiene H. The powerful placebo effect: fact or fiction?.  J Clin Epidemiol. 1997;  50 1311-1318
    CrossrefPubMedGoogle Scholar
  • 32 Hróbjartsson A, Gotzsche P C. Is the placebo powerless?.  N Eng J Med. 2001;  344 1594-1602
    CrossrefPubMedGoogle Scholar

CA Prof. Dr. Karl Bechter

Abteilung Psychiatrie II der Universität Ulm

Ludwig-Heilmeyer-Straße 2

89312 Günzburg

Email: dr.bechter@bkh-guenzburg.de

      >